Canaccord analyst William Plovanic raised the firm’s price target on Staar Surgical to $80 from $79 and keeps a Buy rating on the shares. The analyst believes that, by explaining the optionality that EVO offers, surgeons should be able to convert patients into EVO users although admittedly, the EVO procedures remain at a premium to LASIK.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Staar Surgical price target raised to $79 from $76 at Canaccord
- Staar Surgical reports preliminary Q4 revenue $64M, consensus $65.01M
- This Insider Just Bought Staar Surgical (NASDAQ:STAA) Shares Worth $9.1M
- Staar Surgical price target lowered to $67 from $80 at BTIG
- Staar Surgical price target lowered to $85 from $91 at Stephens